Apocynin

Apocynin

SCHEMBL464770

COc1cc(C(C)=O)ccc1O.COc1cc(C(C)=O)ccc1O

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.75
KMT2A Q03164 2/20 0.75
SLC22A6 Q4U2R8 1/20 0.75
SLC22A8 Q8TCC7 1/20 0.75
RAB9A P51151 1/20 0.75
HTT P42858 1/20 0.72
LMNA P02545 1/20 0.62
HSD17B2 P37059 1/20 0.62
CYP1A2 P05177 1/20 0.60
HSP90AA1 P07900 1/20 0.60
HSP90AB1 P08238 1/20 0.60
BLM P54132 1/20 0.60
KDM4E B2RXH2 1/20 0.58
POLB P06746 1/20 0.58
HDAC6 Q9UBN7 1/20 0.58
ALDH1A1 P00352 2/20 0.56
GAA P10253 2/20 0.56
MAPT P10636 2/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Apocynin SCHEMBL109514 1.00 MEN1 (0.75) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL29364797 1.00 MEN1 (0.75) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL30937977 0.98 MEN1 (0.72) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL28029251 0.98 MEN1 (0.72) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL6650865 0.98 MEN1 (0.72) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL109372 0.96 HTT (0.73) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL108512 0.96 HTT (0.73) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL28429584 0.96 HTT (0.73) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL28537029 0.94 HTT (0.71) MEN1KMT2ASLC22A6SLC22A8RAB9A
Apocynin SCHEMBL28350129 0.93 MEN1 (0.66) MEN1KMT2ASLC22A6SLC22A8RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113215095-A Compositions, media supplements, and stem cell media and methods of culture 生物岛实验室 2021-08-06 CN disclosed
WO-2013138523-A1 METHODS FOR ALTERING LIPIDS IN ALGAE AND YEAST THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2013-09-19 WO disclosed
EP-1381377-B1 A COMPOSITION INCLUDING A GINKGOLIDE AND APOCYNIN WHICH INTERFERES WITH THE ARACHIDONIC ACID CASCADE AKL TECHNOLOGIES LTD (GB) 2012-01-11 EP disclosed
WO-2011114220-A1 NEURO-PROTECTIVE EFFECTS OF ADELOSTEMMA GRACILLIMUM AND ITS ISOLATED COMPOUNDS BIOTECHNOLOGY RESEARCH CORPORATION LIMITED (CN) 2011-09-22 WO disclosed
US-20110086119-A1 Preparation for the relief of disease AKL TECHNOLOGIES LIMITED 2011-04-14 US disclosed
US-20100255211-A1 ACTINIC ENERGY RADIATION CURABLE INK-JET INK AND INK-JET IMAGE FORMING METHOD KONICA MINOLTA IJ TECHNOLOGIES, INC. (JP) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110086119-A1 Preparation for the relief of disease F2, PLA2G7, ALOX15B MEN1 2970/4885KMT2A 4372/4885SLC22A6 4612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.